Evidence check: CYP2D6 in the context of Blutzucker

CYP2D6 is a key cytochrome P450 enzyme primarily involved in the metabolism of many drugs (e.g., antidepressants, beta-blockers, opioids). A direct causal link between CYP2D6 variants and blood glucose levels (glucose homeostasis) is not scientifically established. No robust GWAS or interventional studies show a significant association between CYP2D6 polymorphisms and fasting glucose, HbA1c, or diabetes risk. Indirect effects are conceivable: some drugs metabolized by CYP2D6 (e.g., beta-blockers) can influence insulin sensitivity, but this is drug-dependent and not a direct genetic effect. Consumer DNA tests that mention CYP2D6 in the context of blood sugar overstate the evidence. The clinical relevance of CYP2D6 lies in pharmacogenetics, not metabolic diagnostics. Blood sugar assessment should rely on established markers like fasting glucose, HbA1c, and oral glucose tolerance test, not CYP2D6 genotypes. Evidence grade: unclear/mechanistic.